The last $400M round was originally targeted at $200M but was 2x oversubscribed; Lamm says every round has been >2x oversubscribed, signaling strong investor demand and that the c…

Colossal's vertical integration across genome engineering, artificial wombs, and DNA synthesis at planetary scale creates a civilization-tech platform with applications from de-ex…

Strong investor demand validates the platform; $635M total raised with last round targeting $200M but closing at $400M, and Lamm expects further raises to fund the expanding pipel…

Vertical integration via Viagen acquisition gives Colossal best-in-class cloning infrastructure (80% efficiency vs 2% typical), a critical bottleneck for endangered-species produc…

Colossal's gene-drive technology can eradicate the New World screwworm in 6-7 months versus the USDA's 8-year, $1.5B chemical program, representing a massive government-contract o…

Technical execution far surpassing early milestones — told 5-7 edits in 5 years would be great, now doing hundreds and pushing a new construct for thousands of simultaneous edits,…